论文部分内容阅读
2019新型冠状病毒(2019-nCoV)是武汉不明原因肺炎的致病原.2019-nCoV在遗传学上与一种蝙蝠来源的新型冠状病毒比较接近,与SARS-CoV、MERS-CoV同为β属冠状病毒.目前临床上常用的抗病毒药物,包括神经氨酸酶抑制剂(奥司他韦、帕拉米韦、扎那米韦等)、更昔洛韦、阿昔洛韦、利巴韦林等药物对2019-nCoV均无效,不建议临床应用.目前研究证实可能有效的药物包括:瑞德西韦、洛匹那韦/利托那韦、洛匹那韦/利托那韦联合干扰素-β、恢复期血浆、单克隆抗体.但这些药物在2019-nCoV肺炎患者中的疗效和安全性有待进一步临床实验证实.“,”The recent outbreak of respiratory illness in Wuhan,China is caused by a novel coronavirus,named 2019-nCoV,which is genetically close to a bat-derived coronavirus.2019-nCoV is categorized as beta genus coronavirus,same as the two other strains-severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV).Antiviral drugs commonly used in clinical practice,including neuraminidase inhibitors (osehamivir,paramivir,zanamivir,etc.),ganciclovir,acyclovir and ribavirin,are invalid for 2019-nCoV and not recommended.Drugs are possibly effective for 2019-nCoV include:remdesivir,lopinavir/ritonavir,lopinavir/ritonavir combined with interferon-β,convalescent plasma,and monoclonal antibodies.But the efficacy and safety of these drugs for 2019-nCoV pneumonia patients need to be assessed by further clinical trials.